(19)
(11) EP 4 823 626 A1

(12)

(43) Date of publication:
21.10.2026 Bulletin 2026/43

(21) Application number: 24904880.2

(22) Date of filing: 12.12.2024
(51) International Patent Classification (IPC): 
A61K 47/68(2017.01)
C07K 16/28(2006.01)
A61K 39/395(2006.01)
A61K 31/4745(2006.01)
A61K 47/65(2017.01)
A61P 35/00(2006.01)
C07D 491/22(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 39/395; A61P 35/00; C07D 491/22; C07K 16/28; C07K 2317/24; C07K 2317/90; C07K 2317/92; C07K 2317/94; A61K 47/68037; A61K 47/6889; A61K 47/6851; A61K 47/6849
(86) International application number:
PCT/US2024/059794
(87) International publication number:
WO 2025/128837 (19.06.2025 Gazette 2025/25)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 13.12.2023 CN 202311712634

(71) Applicant: SystImmune, Inc.
Redmond WA 98052 (US)

(72) Inventors:
  • ZHU, Yi
    Redmond, Washington 98052 (US)
  • ZHUO, Shi
    Chengdu, Sichuan 611130 (CN)
  • WAN, Weili
    Chengdu, Sichuan 611130 (CN)
  • ZHANG, Yong
    Chengdu, Sichuan 611130 (CN)
  • LI, Gangrui
    Chengdu, Sichuan 611130 (CN)

(74) Representative: Mathys & Squire 
32 London Bridge Street The Shard
London SE1 9SG
London SE1 9SG (GB)

   


(54) ANTI-CLAUDIN18.2 ANTIBODY-CAMPTOTHECIN DRUG CONJUGATE AND PHARMACEUTICAL USE THEREOF